Evidence map›Paper›PMID 42622657›Full record

ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2026

Multicenter ProKnow-based plan evaluation of postprostatectomy salvage radiotherapy patients using SPPORT and RADICALS-HD trial-defined dose constraints.

Michael Keilholz, Erik F Moar, Frederike Brose, Sebastian H Maier, Claus Belka, Paul Rogowski, Matthias Zähringer, Jan C Peeken, Stephanie E Combs, Stephan Schönecker and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Michael KeilholzDepartment of Radiation Oncology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany. Michael.Keilholz@med.uni-muenchen.de.ORCID http://orcid.org/0009-0006-9885-9893
Erik F MoarDepartment of Radiation Oncology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany.
Frederike BroseDepartment of Radiation Oncology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany.
Sebastian H MaierDepartment of Radiation Oncology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany.
Claus BelkaDepartment of Radiation Oncology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany.
Paul RogowskiDepartment of Radiation Oncology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany.
Matthias ZähringerBavarian Cancer Research Center (BZKF), Munich, Germany.
Jan C PeekenBavarian Cancer Research Center (BZKF), Munich, Germany.
Stephanie E CombsBavarian Cancer Research Center (BZKF), Munich, Germany.
Stephan SchöneckerDepartment of Radiation Oncology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany.
Florian PutzBavarian Cancer Research Center (BZKF), Munich, Germany.
Christoph SüßBavarian Cancer Research Center (BZKF), Munich, Germany.
Marius TreutweinBavarian Cancer Research Center (BZKF), Munich, Germany.
Vasiliki AngnostatouDepartment of Radiation Oncology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany.
Nina Schmidt-HegemannDepartment of Radiation Oncology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSalvage radiotherapy (sRT) after radical prostatectomy is the only curative treatment for patients with biochemical recurrence. Sparing organs at risk (OAR) is essential to minimize long-term toxicity. This multicenter study analyzed radiotherapy plans from Bavarian university centers within the Bavarian Cancer Research Center (BZKF) using dose-volume constraints from the SPPORT and RADICALS-HD trials.

methodsIn this retrospective multicenter analysis, 117 patients treated with prostate bed sRT were included. Radiotherapy plans were anonymized and evaluated using ProKnow (Elekta, Stockholm, Sweden). Scorecards based on SPPORT and RADICALS-HD dose-volume constraints were used to assess plan quality. Planning metrics, including planning target volume (PTV), D95, conformality index, and V66, were recorded, and their correlations with OAR dose were analyzed.

resultsThe median PTV was 213.9 cm

conclusionThis multicenter analysis demonstrates that dose-volume objectives in the postoperative salvage setting can be reliably assessed across centers and are met in the majority of cases. ProKnow enables structured and objective plan evaluation and serves as a useful tool for standardized quality assurance.

Indexed as

Dose–volume constraintsOrgans at riskOrgan-sparing proceduresProstate cancerRadiotherapy plan quality

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.